Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 3/2021

01-09-2021 | Osteoarthrosis | Review

Osteoarthritis: Current Molecular Biomarkers and the Way Forward

Authors: Virginia Byers Kraus, Morten A. Karsdal

Published in: Calcified Tissue International | Issue 3/2021

Login to get access

Abstract

The ultimate hope of researchers and patients is a pathway to development of treatments for osteoarthritis to modify the disease process in addition to the symptoms. However, development of disease modifying drugs requires objective endpoints such as measures of joint structure, joint tissue homeostasis and/or joint survival–measures such as provided by imaging biomarkers, molecular biomarkers and joint replacement frequency, respectively. Although biomarkers supporting investigational drug use and drug approval include surrogate endpoints that may not necessarily reflect or directly correlate with the clinical outcome of interest, a formal biomarker qualification process currently exists that is a rigorous three stage process that yields biomarker approvals (or denials) for specific contexts of use. From a cost perspective, biochemical biomarkers are the ‘ones to beat’; however, even well-validated biomarkers may not cross the translation gaps for eventual use in healthcare unless they offer an advantage in terms of cost per quality adjusted life year. This review summarizes the case FOR and AGAINST biomarkers in drug development and highlights the current data for a subset of biomarkers in the osteoarthritis research field informing on cartilage homeostasis, joint inflammation and altered subchondral bone remodeling.
Literature
1.
The Voice of the Patient: Osteoarthritis Report PC, Copenhaver C, Dernier D, Geller K, Hanson B, Harvey K, Johnson F, Kraus V, Lester G, McGrath E, Shuey D, Tuan R, Tucci A, Wyatt J (2017) Osteoarthritis patient-focused drug development: voice of the patient report. In: The voice of the patient. Arthritis Foundation, Washington, DC
2.
Thomas D, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M (2016) Clinical development success rates 2006–2015. In: Biotechnology Innovation Organization (BIO), biomedtracker and amplion, pp 1–26
3.
Karsdal MA, Christiansen C, Ladel C, Henriksen K, Kraus VB, Bay-Jensen AC (2014) Osteoarthritis—a case for personalized health care? Osteoarthr Cartil 22:7–16CrossRef
4.
Bernard SA, Chelminski PR, Ives TJ, Ranapurwala SI (2018) Management of pain in the United States—a brief history and implications for the opioid epidemic. Health Serv Insights 11:1178632918819440PubMedPubMedCentral
5.
Miller RE, Block JA, Malfait AM (2017) Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol 29:110–118PubMedPubMedCentralCrossRef
6.
LaBranche TP, Bendele AM, Omura BC, Gropp KE, Hurst SI, Bagi CM, Cummings TR, Grantham LE 2nd, Shelton DL, Zorbas MA (2017) Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann Rheum Dis 76:295–302PubMedCrossRef
7.
Sand JM, Knox AJ, Lange P, Sun S, Kristensen JH, Leeming DJ, Karsdal MA, Bolton CE, Johnson SR (2015) Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res 16:69PubMedPubMedCentralCrossRef
8.
Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC (2010) Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease? Clin Biochem 43:793–804PubMedCrossRef
9.
Siebuhr AS, He Y, Gudmann NS, Gram A, Kjelgaard-Petersen CF, Qvist P, Karsdal MA, Bay-Jensen AC (2014) Biomarkers of cartilage and surrounding joint tissue. Biomark Med 8:713–731PubMedCrossRef
10.
Felson D, Niu J, Sack B, Aliabadi P, McCullough C, Nevitt MC (2013) Progression of osteoarthritis as a state of inertia. Ann Rheumatol Dis 72:924–929CrossRef
11.
FDA (2019) Drug development tool qualification process: transparency provisions
12.
13.
Kraus V, Hsueh M-F (2020) Biomarkers and Osteoarthritis. In: Ginsburg G, Willard H, Tsalik E, Woods C (eds) Genomic and Precision Medicine. Elsevier, p 429–444
14.
Karsdal MA, Krarup H, Sand JM, Christensen PB, Gerstoft J, Leeming DJ, Weis N, Schaffalitzky de Muckadell OB, Krag A (2014) Review article: the efficacy of biomarkers in chronic fibroproliferative diseases—early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 40:233–249PubMedCrossRef
15.
Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS (2015) Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr Cartil 23:1233–1241CrossRef
16.
Huang Z, Chen J, Hu QS, Huang Q, Ma J, Pei FX, Shen B, Kraus VB (2019) Meta-analysis of pain and function placebo responses in pharmacological osteoarthritis trials. Arthritis Res Ther 21:173PubMedPubMedCentralCrossRef
17.
Henriksen K, Bohren KM, Bay-Jensen AC, Karsdal MA (2010) Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? Biomarkers 15:195–204PubMedCrossRef
18.
Bay-Jensen AC, Sondergaard BC, Christiansen C, Karsdal MA, Madsen SH, Qvist P (2010) Biochemical markers of joint tissue turnover. Assay Drug Dev Technol 8:118–124PubMedCrossRef
19.
Zhang W, Robertson WB, Zhao J, Chen W, Xu J (2019) Emerging trend in the pharmacotherapy of osteoarthritis. Front Endocrinol 10:431CrossRef
20.
Kraus V, Vincent T (2020) Osteoarthritis. In: Goldman L, Schafer A (eds) Goldman-Cecil Medicine. Elsevier, Philadelphia, PA, pp 1698–1703
21.
Karsdal MA, Woodworth T, Henriksen K, Maksymowych WP, Genant H, Vergnaud P, Christiansen C, Schubert T, Qvist P, Schett G, Platt A, Bay-Jensen AC (2011) Biochemical markers of ongoing joint damage in rheumatoid arthritis–current and future applications, limitations and opportunities. Arthritis Res Therapy 13:215CrossRef
22.
Bay-Jensen AC, Reker D, Kjelgaard-Petersen CF, Mobasheri A, Karsdal MA, Ladel C, Henrotin Y, Thudium CS (2016) Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthr Cartil 24:9–20CrossRef
23.
Huebner JL, Bay-Jensen AC, Huffman KM, He Y, Leeming DJ, McDaniel GE, Karsdal MA, Kraus VB (2014) Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis. Arthritis Rheumatol (Hoboken, NJ) 66:2440–2449CrossRef
24.
Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Brauer R, Danielsen I, Christiansen C, Qvist P, Karsdal MA (2006) Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthr Cartil 14:738–748CrossRef
25.
Kraus VB, Collins JE, Hargrove D, Losina E, Nevitt M, Katz JN, Wang SX, Sandell LJ, Hoffmann SC, Hunter DJ (2017) Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium. Ann Rheum Dis 76:186–195PubMedCrossRef
26.
Bjerre-Bastos J, Bay-Jensen A-C, Karsdal M, Byrjalsen I, Andersen J, Riis B, Christiansen C, Bihlet A (2019) Biomarkers of bone and cartilage turnover CTX-I and CTXII predict total joint replacements in osteoarthritis. Osteoarthr Cartil 27(S31):12
27.
Luo Y, He Y, Reker D, Gudmann NS, Henriksen K, Simonsen O, Ladel C, Michaelis M, Mobasheri A, Karsdal M, Bay-Jensen AC (2018) A novel high sensitivity type II collagen blood-based biomarker, PRO-C2, for assessment of cartilage formation. Int J Mol Sci 19:3485PubMedCentralCrossRef
28.
Oganesian A, Zhu Y, Sandell LJ (1997) Type IIA procollagen amino propeptide is localized in human embryonic tissues. J Histochem Cytochem 45:1469–1480PubMedCrossRef
29.
Styrkarsdottir U, Lund SH, Thorleifsson G, Zink F, Stefansson OA, Sigurdsson JK, Juliusson K, Bjarnadottir K, Sigurbjornsdottir S, Jonsson S, Norland K, Stefansdottir L, Sigurdsson A, Sveinbjornsson G, Oddsson A, Bjornsdottir G, Gudmundsson RL, Halldorsson GH, Rafnar T, Jonsdottir I, Steingrimsson E, Norddahl GL, Masson G, Sulem P, Jonsson H, Ingvarsson T, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K (2018) Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, IL11, COL11A1 and 13 more new loci associated with osteoarthritis. Nat Genet 50:1681–1687PubMedCrossRef
30.
Tachmazidou I, Hatzikotoulas K, Southam L, Esparza-Gordillo J, Haberland V, Zheng J, Johnson T, Koprulu M, Zengini E, Steinberg J, Wilkinson JM, Bhatnagar S, Hoffman JD, Buchan N, Suveges D, Yerges-Armstrong L, Smith GD, Gaunt TR, Scott RA, McCarthy LC, Zeggini E (2019) Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet 51:230–236PubMedPubMedCentralCrossRef
31.
Luo Y, Higgins N, He Y, Byrjalsen I, Andersen J, Bihlet A, Karsdal M, Bay-Jensen A (2019) Identification of superior responders to a bone and cartilage centric treatment in osteoarthritis: low levels of cartilage formation may provide an opportunity to stimulate formation. Osteoarthr Cartil 27:S61CrossRef
32.
Hsueh MF, Onnerfjord P, Bolognesi MP, Easley ME, Kraus VB (2019) Analysis of "old" proteins unmasks dynamic gradient of cartilage turnover in human limbs. Sci Adv 5:e3203CrossRef
33.
Hunter D, Deveza L, Collins J, Losina E, Nevitt M, Roemer F, Guermazi A, Bowes M, Dam E, Eckstein F, Lynch J, Katz J, Kwoh C, Hoffman S, Kraus V (2019) Multivariable modelling of biomarker data from the phase 1 Foundation for NIH Osteoarthritis Biomarkers Consortium. Ann Rheum Dis 76:186–195
34.
Tarhan S, Unlu Z (2003) Magnetic resonance imaging and ultrasonographic evaluation of the patients with knee osteoarthritis: a comparative study. Clin Rheumatol 22:181–188PubMedCrossRef
35.
Song IH, Althoff CE, Hermann KG, Scheel AK, Knetsch T, Schoenharting M, Werner C, Burmester GR, Backhaus M (2008) Knee osteoarthritis. Efficacy of a new method of contrast-enhanced musculoskeletal ultrasonography in detection of synovitis in patients with knee osteoarthritis in comparison with magnetic resonance imaging. Ann Rheum Dis 67:19–25PubMedCrossRef
36.
Hsueh M-F, Lu Y-J, Wellman S, Bolognesi M, Kraus VB (2018) Functional folate receptor cell-associated inflammatory cytokines predict the progression of knee osteoarthritis. Osteoarthr Cartil 26(S121):228
37.
Hsueh M-F, Zhang X, Wellman S, Bolognesi M, Kraus V (2019) Synergistic roles of macrophages and neutrophils in osteoarthritis progression. Arhthritis Rheum (in review)
38.
Kraus VB, McDaniel G, Huebner JL, Stabler TV, Pieper CF, Shipes SW, Petry NA, Low PS, Shen J, McNearney TA, Mitchell P (2016) Direct in vivo evidence of activated macrophages in human osteoarthritis. Osteoarthr Cartil 24:1613–1621CrossRef
39.
40.
Haraden CA, Huebner JL, Hsueh MF, Li YJ, Kraus VB (2019) Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation. Arthritis Res Ther 21:146PubMedPubMedCentralCrossRef
41.
Deveza LA, Kraus VB, Collins JE, Guermazi A, Roemer FW, Nevitt MC, Hunter DJ (2018) Is synovitis detected on non-contrast-enhanced magnetic resonance imaging associated with serum biomarkers and clinical signs of effusion? Data from the osteoarthritis initiative. Scand J Rheumatol 47:235–242PubMedCrossRef
42.
Huang ZY, Stabler T, Pei FX, Kraus VB (2016) Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. Osteoarthr Cartil 24:1769–1775CrossRef
43.
Boer CG, Radjabzadeh D, Medina-Gomez C, Garmaeva S, Schiphof D, Arp P, Koet T, Kurilshikov A, Fu J, Ikram MA, Bierma-Zeinstra S, Uitterlinden AG, Kraaij R, Zhernakova A, van Meurs JBJ (2019) Intestinal microbiome composition and its relation to joint pain and inflammation. Nat Commun 10:4881PubMedPubMedCentralCrossRef
44.
Panagopoulos PK, Lambrou GI (2018) Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications. J Musculoskel Neuronal Interact 18:304–319
45.
Siebuhr AS, Bay-Jensen AC, Leeming DJ, Plat A, Byrjalsen I, Christiansen C, van de Heijde D, Karsdal MA (2013) Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Therapy 15:R86CrossRef
46.
Gudmann NS, Junker P, Juhl P, Thudium CS, Siebuhr AS, Byrjalsen I, Karsdal MA, Bay-Jensen AC (2018) Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis. Clin Exp Rheumatol 36:829–835PubMed
47.
Kjelgaard-Petersen C, Siebuhr AS, Christiansen T, Ladel C, Karsdal M, Bay-Jensen AC (2015) Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis. Biomarkers 20:547–556PubMedCrossRef
48.
Kjelgaard-Petersen CF, Platt A, Braddock M, Jenkins MA, Musa K, Graham E, Gantzel T, Slynn G, Weinblatt ME, Karsdal MA, Thudium CS, Bay-Jensen AC (2018) Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis. Arthritis Rheumatol 70:1419–1428PubMedPubMedCentralCrossRef
49.
Huang Z, Kraus VB (2016) Does lipopolysaccharide-mediated inflammation have a role in OA? Nat Rev Rheumatol 12:123–129PubMedCrossRef
50.
Goldring MB, Goldring SR (2010) Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 1192:230–237PubMedCrossRef
51.
Engbersen M, Huang Z, Kraus V (2016) Bone biomarkers related to osteoarthritis. In: Preedy V (ed) Biomarkers in disease: methods, discoveries and applications. Springer, Dordrecht, pp 1–29
52.
Chou CH, Wu CC, Song IW, Chuang HP, Lu LS, Chang JH, Kuo SY, Lee CH, Wu JY, Chen YT, Kraus VB, Lee MT (2013) Genome-wide expression profiles of subchondral bone in osteoarthritis. Arthritis Res Ther 15:R190PubMedPubMedCentralCrossRef
53.
Chou CH, Lee CH, Lu LS, Song IW, Chuang HP, Kuo SY, Wu JY, Chen YT, Kraus VB, Wu CC, Lee MT (2013) Direct assessment of articular cartilage and underlying subchondral bone reveals a progressive gene expression change in human osteoarthritic knees. Osteoarthr Cartil 21:450–461CrossRef
54.
Kraus VB, Collins JE, Charles HC, Pieper CF, Whitley L, Losina E, Nevitt M, Hoffmann S, Roemer F, Guermazi A, Hunter DJ (2018) Predictive validity of radiographic trabecular bone texture in knee osteoarthritis: the osteoarthritis research society international/foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium. Arthritis Rheumatol 70:80–87PubMedCrossRef
55.
Bettica P, Cline G, Hart DJ, Meyer J, Spector TD (2002) Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 46:3178–3184PubMedCrossRef
56.
O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC (2017) Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol 14:169–186PubMedCrossRef
57.
Collins JE, Losina E, Nevitt MC, Roemer FW, Guermazi A, Lynch JA, Katz JN, Kent Kwoh C, Kraus VB, Hunter DJ (2016) Semiquantitative Imaging Biomarkers of Knee Osteoarthritis Progression: Data From the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium. Arthritis Rheumatol (Hoboken, NJ) 68:2422–2431CrossRef
58.
Hunter D, Nevitt M, Losina E, Kraus V (2014) Biomarkers for osteoarthritis: current position and steps towards further validation. Best Pract Res 28:61–71CrossRef
59.
Kraus V, Hargrove D, Hunter D, Renner J, Jordan J (2014) Establishment of reference intervals for osteoarthritis related biomarkers—the FNIH/OARSI OA Biomarkers Consortium. Osteo Cartilage 22:podium presentation
60.
Food and Drug Administration-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource. In: FDA, Silver Spring, MD
61.
Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegard D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M (2011) Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr Cartil 19:515–542CrossRef
62.
Kraus VB, Blanco FJ, Englund M, Henrotin Y, Lohmander LS, Losina E, Onnerfjord P, Persiani S (2015) OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage 23:686–697PubMedPubMedCentralCrossRef
63.
March L, Cross M, Lo C, Arden N, Gates L, Leyland K, Hawker G, King L (2016) Osteoarthritis: a serious disease. Access Date Access 2016
Metadata
Title
Osteoarthritis: Current Molecular Biomarkers and the Way Forward
Authors
Virginia Byers Kraus
Morten A. Karsdal
Publication date
01-09-2021
Publisher
Springer US
Published in
Calcified Tissue International / Issue 3/2021
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-020-00701-7

Other articles of this Issue 3/2021

Calcified Tissue International 3/2021 Go to the issue

Review

The Genetic Epidemiology of Joint Shape and the Development of Osteoarthritis

Editorial

Osteoarthritis—Slow but Steady Steps Forward

Review

The Bone Cartilage Interface and Osteoarthritis

Review

Models of Osteoarthritis: Relevance and New Insights

Review

“Lessons from Rare Forms of Osteoarthritis”

Review

Targeting Dysregulation of Metalloproteinase Activity in Osteoarthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits